Zydus Cadila has received the tentative approval from the USFDA to market Lorcaserin Hydrochloride Tablets (US RLD - Belviq Tablets), 10 mg. The drug is used together with diet and exercise to treat obesity. It will be manufactured at the group's formulations manufacturing facility at $132.
The group now has 278 approvals and has so far filed over 330 ANDAS since the commencement of the filing process in FY 2003-04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.257.65 as compared to the previous close of Rs. 254.4. The total number of shares traded during the day was 75934 in over 1614 trades.
The stock hit an intraday high of Rs. 259.1 and intraday low of 251.85. The net turnover during the day was Rs. 19419236.